Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway by Huang, Haizhi et al.
Marshall University
Marshall Digital Scholar
Pharmaceutical Science and Research Faculty Research
Summer 7-30-2015
Myricetin inhibits proliferation of cisplatin-resistant
cancer cells through a p53-dependent apoptotic
pathway
Haizhi Huang
Allen Y. Chen
Xingqian Ye
Bingyun Li
Yon Rojanasakul
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sp_psr
Part of the Medical Pharmacology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Pharmaceutical Science and Research by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, martj@marshall.edu.
Recommended Citation
Huang H, Chen AY, Ye X, Li B, Rojanasakul Y, Rankin GO, Chen YC. Myricetin inhibits proliferation of cisplatin-resistant cancer cells
through a p53-dependent apoptotic pathway. International Journal of Oncology. 2015;47(4):1494-1502.
Authors
Haizhi Huang, Allen Y. Chen, Xingqian Ye, Bingyun Li, Yon Rojanasakul, Gary O. Rankin, and Yi Charlie
Chen
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sp_psr/104
INTERNATIONAL JOURNAL OF ONCOLOGY  47:  1494-1502,  20151494
Abstract. Cisplatin is a commonly used drug for cancer 
treatment by crosslinking DNA, leading to apoptosis of 
cancer cells, resistance to cisplatin treatment often occurs, 
leading to relapse. Therefore, there is a need for the devel-
opment of more effective treatment strategies that can 
overcome chemoresistance. Myricetin is a flavonoid from 
fruits and vegetables, showing anticancer activity in various 
cancer cells. In this study, we found myricetin exhibited 
greater cytotoxicity than cisplatin in two cisplatin-resistant 
ovarian cancer cell lines, OVCAR-3 and A2780/CP70, and it 
was less cytotoxic to the normal ovarian cell line IOSE-364. 
Myricetin selectively induced apoptosis in both cisplatin-
resistant cancer cell lines, but did not induce apoptosis in 
the normal ovarian cell line. It induced both Bcl-2 family-
dependent intrinsic and DR5 dependent extrinsic apoptosis 
in OVCAR-3 cells. P53, a multifunctional tumor suppressor, 
regulated apoptosis in OVCAR-3 cells through a Bcl-2 
family protein-dependent pathway. Myricetin did not induce 
cell cycle arrest in either ovarian cancer cell line. Because of 
its potency and selectivity against cisplatin-resistant cancer 
cells, myricetin could potentially be used to overcome cancer 
chemoresistance against platinum-based therapy.
Introduction
The human health and life are under constant serious threat 
of cancer. Surgery, radiation, and chemotherapy have been 
the most commonly utilized methods for therapy of ovarian 
cancer. Recently, chemotherapy has become the predominant 
mode of treatment. Platinum drugs, such as cisplatin and its 
analogues, are the most frequently used agents for the treat-
ment of human cancer. Initially, cisplatin responsiveness is 
high, however, a large number of cancer patients will relapse 
with cisplatin-resistant disease due to many mechanisms 
including increased detoxification of the drug, changes in 
cellular efflux and uptake of the drug, increased DNA repair 
and inhibition of apoptosis (1). Moreover, it causes unaccept-
able rates of normal cell toxicity and a number of side-effects, 
such as nephrotoxicity, neurotoxicity, ototoxicity electrolyte 
disturbance, myelotoxicity, hemolytic anemia, nausea and 
vomiting (2-5). Therefore, novel therapies and more selective 
drugs are needed for the treatment of human cancer (6).
The cell cycle is the series of events that take place in a 
cell leading to its division and duplication, resulting in two 
daughter cells. It can be divided into three periods: interphase 
(G1, S and G2 phases), the mitotic phase (M phase) and cyto-
kinesis. A dysregulation of cell cycle components may lead 
to tumor formation (7), and investigational anticancer drugs 
have recently focused on the molecular targets involved in 
cell cycle control mechanisms (8,9).
Apoptosis is a process of programmed cell death (PCD) 
that occurs in multicellular organisms. Excessive apoptosis 
causes atrophy, whereas defective apoptotic processes result 
in uncontrolled cell proliferation, implicated in a wide 
variety of diseases such as cancer. It has been reported that 
a decreased susceptibility of cancer cells to apoptosis was 
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tightly associated with drug resistance. Therefore, inducing 
apoptosis in cancer cells may be a promising strategy to 
overcome resistance (6). Many mechanisms are connected to 
the failure to develop apoptosis in cancer cells, including the 
expression of P-glycoprotein and p53 mutations. Two major 
pathways leading to apoptosis, the intrinsic (mitochondrial) 
and extrinsic (receptor-mediated) pathways, have been 
delineated. The Bcl-2 protein family regulates the intrinsic 
apoptotic pathway by controlling the permeability of the 
mitochondrial membrane and the release of the pro-apoptotic 
factors (10). Tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL), including Apo2L/TRAIL, regulates the 
extrinsic apoptotic pathway by engaging its receptor.
Flavonoids are natural polyphenols present in a variety 
of foods, especially fruits and vegetables. The anticancer 
activity of flavonoids isolated from plants have been widely 
studied. It has been reported that flavonoids display anticancer 
characteristics and might be able to prevent oxidation and 
inflammation, diminish angiogenesis and cell proliferation, 
and induce apoptosis (11). Myricetin (Fig. 1A) is a member of 
the flavonoid class of phenolic compounds with antioxidant 
properties (12). It can be found in fruits, vegetables, nuts, 
berries, tea and red wine (13,14). Previous studies have 
reported myricetin induces apoptosis in various cancer cells, 
such as in hepatoma, pancreatic cancer, esophageal cancer 
and colon carcinoma cells (15-18).
In this study, we examined the effects of myricetin apop-
tosis induction and cell cycle arrest in two platinum-resistant 
ovarian cancer cell lines: A2780/CP70 and OVCAR-3. The 
mechanisms involved in the effects of myricetin were also 
investigated.
Materials and methods
Cell culture and reagents. Human ovarian cancer cell 
lines, OVCAR-3 and A2780/CP70, were kindly provided by 
Dr B. Jiang, Department of Microbiology, Immunology, and 
Cell Biology, West Virginia University, Morgantown, WV, 
USA. IOSE-364, normal ovarian surface epithelial cells from 
healthy women, but immortalized with SV40 T/t, were a gift 
from Dr N. Auersperg at the University of British Columbia, 
Canada (19). All cell lines were maintained in RPMI-1640 
medium (Sigma, St. Louis, MO, USA) supplemented with 
10% US-qualified fetal bovine serum (Invitrogen, Grand 
Island, NY, USA). All cells were maintained in a humidified 
incubator with 5% CO2 at 37˚C. Myricetin was purchased 
from J&k Chemical Technology (Beijing, China). It was 
dissolved in dimethyl sulfoxide (DMSO) to make stock 
solutions of 100 mM, and equal amounts of DMSO were 
included in controls for every experiment. The primary 
antibodies against caspase-3, -7, -8, and -9, Bax, Bcl-2, DR5, 
Puma, FADD, and p21 were purchased from Cell Signaling 
Technology, Inc. (Danvers, MA, USA). The primary anti-
bodies against p53, cmyc, Bcl-xl and GAPDH were purchased 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Cell viability. Cell growth inhibition was determined by 
measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) dye absorbance. The cells (1x104) were 
seeded into 96-well, incubated at 37˚C. Cells were incubated 
overnight for attaching to the bottom and then treated with 
different concentrations of myricetin (5-80 µM) or DMSO 
(as vehicle). After 24 h, the medium was removed, and 100 µl 
MTT (1 mg/ml) were added to each well and then incubated 
at 37˚C for 4 h in the dark. After removing the supernatant, 
the formed formazan crystals were dissolved in 200 µl 
DMSO, and absorbance was measured at 570 nm.
Chicken chorioallantoic membrane assay. Specific pathogen-
free fertile chicken eggs (Charles River Laboratories, North 
Franklin, CT, USA) were slowly turned by an automatic egg 
turner (G.q.F. Manufacturing Co., Savannah, GA, USA) and 
incubated at 37.5˚C. The cells (1.2x106) were suspended in 
20 µl FBS-free medium, mixed with 80 µl of Matrigel (BD 
Bioscience) and 0- or 20-µM myricetin, incubated on an auto-
claved silicone mat for 30 min for gelation, and implanted 
into the chorioallantoic membrane (CAM) of a 9-day-old 
chicken embryo. After incubating another 5 days, the tumor 
implants were measured for tumor weight.
Flow cytometry analysis of cell apoptosis. The apoptosis 
effects of myricetin on ovarian cells were determined by 
Alexa Fluor 488 Annexin V/Dead Cell Apoptosis kit from 
Invitrogen. A2780/CP70, OVCAR-3 and IOSE-364 cells 
(106/dish) treated with myricetin or DMSO for 24 h were 
washed with cold PBS twice and re-suspended in binding 
buffer. An aliquot of 100 µl of the cell solution (1x105 cells) 
was transferred to a 5-ml tissue culture tube. Subsequently, 
5 µl of FITC Annexin V and 1 µl propidium iodide (PI) 
were added to the cells. The cells were gently vortexed and 
incubated for 15 min at room temperature in the dark. The 
next step involved the addition of 400 µl of 1X binding buffer 
to each tube. The samples were analyzed by flow cytometry 
(FACSCalibur system, BD Biosciences, San Jose, CA, USA).
Apoptosis assessment by Hoechst 33342 staining. OVCAR-3 
cells (106/dish) treated with various concentrations of myric-
etin and pifithrin-α (PFT-α) (Sigma) for 24 h were washed 
with cold PBS and stained with 10 µg/ml Hoechst 33342 
(Sigma) in PBS for 10 min in the dark at 37˚C. Cell apoptosis 
was examined under a fluorescence microscope (Zeiss).
Flow cytometry analysis of the cell cycle. Cells treated 
with various concentrations of myricetin for 24 h were 
digested by trypsin, collected by 1,000 rpm centrifuga-
tion for 10 min, and then washed with cold PBS. The cell 
pellets were suspended with 70% ethanol, stored at -20˚C. 
After centrifugation at 1,000 rpm for 6 min, the cell pellets 
were re-suspended in PBS, collected by centrifugation, and 
incubated with 180 µg/ml RNase A at 37˚C for 15 min. Flow 
cytometry (FACSCalibur system, BD Biosciences) was used 
for detection after 50 µg/ml propidium iodide (final concen-
tration) was added to cell pellets for 15-min staining. Data 
were plotted and analyzed by using FCS software (De Novo 
Software, Los Angeles, CA, USA).
Caspase-3/7 and caspase-9 assay. A2780/CP70 and 
OVCAR-3 cells were seeded into 96-well plates (1x104/well) 
and incubated overnight at 37˚C. Cells were treated with 
different concentrations of myricetin (5-20 µM) or DMSO 
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for 4 h. After treatment, Caspase-Glo 3/7 or Caspase-Glo 9 
Assay kit (Promega) was used to detect the caspase-3/7 or 
caspase-9 enzymatic activities in both ovarian cancer cell 
lines. Enzymatic activities were normalized by total protein 
levels and were expressed as a percentage of the untreated 
control.
Western blotting. Ovarian cancer cells were seeded in 60-mm 
dishes at the concentration of 106/dish, incubated overnight, 
and then treated with various concentrations of myricetin 
for 24 h. The cells were lysed in 100 µl mammalian protein 
extraction reagent including 1 µl Halt protease, 1 µl phos-
phatase inhibitor, and 2 µl EDTA (M-PER, Pierce, Rockford, 
IL, USA). Total protein levels were determined by a BCA 
Protein Assay kit (Pierce). The cell lysates were separated by 
SDS-PAGE and blotted onto a nitrocellulose membrane with 
a Mini-Protean 3 system (Bio-Rad, Hercules, CA, USA). 
The membranes were blocked in 5% non-fat milk (dissolved 
in Tris-buffer saline containing 0.1% Tween-20) for 1 h at 
room temperature. The membranes were incubated with 
the primary antibodies and secondary antibody dilutions, 
washed with TBST. The antigen-antibody complex was visu-
alized with the SuperSignal West Dura Extended Duration 
Substrate (Pierce).
Transfection with small interfering RNA (siRNA). OVCAR-3 
cells were seeded in 60-mm dishes at 5x105/dish and incu-
bated overnight before transfection with p53 siRNA, p21 
siRNA or control siRNA (Santa Cruz) using jetPRIME™ 
DNA and siRNA transfection reagent (VWR International, 
Radnor, PA, USA) according to the manufacturer's protocol. 
After 24 h, cells were treated with myricetin or DMSO. Cell 
lysates were collected for western blotting to test Bad, Bax, 
Bcl-xl, cmyc, p53 and p21 proteins.
Statistical analysis. The experiments were performed at 
least three times. Results were expressed as mean ± standard 
error of mean (SEM) using Microsoft Excel (2007). SPSS 
(Version 18.0 for Windows) was used to perform statistical 
assessment. The results were analyzed using post hoc test 
(2-sided Dunnett's test) and one-way analysis of variance 
(ANOVA) to test differences between each treatment and 
control. A p-value of <0.05 was considered statistically 
significant.
Results
Effect of myricetin on ovarian cancer cell proliferation. 
MTT assay was performed after treatment of ovarian cancer 
and normal ovarian cells with myricetin to investigate the 
effect of myricetin on the viability of platinum-resistant 
ovarian cancer cells. We observed that compared with 
controls (myricetin 0 µM), myricetin significantly reduced 
the viability of A2780/CP70 and OVCAR-3. Cell viability 
with myricetin treatment (5-80 µM) for 24 h ranged from 
93.8 to 17.4% (p<0.05) for A2780/CP70 cells (Fig. 1B). 
Figure 1. Myricetin inhibits cell viability in ovarian cancer cells. (A) Structure of myricetin. (B) Cells (1x104/well) were seeded in 96-well plates, incu-
bated overnight, and then treated with myricetin for 24 h. Cell viability was determined by an MTT-based method and expressed as percentages of control. 
(C) Myricetin suppressed OVCAR-3 cells growth in vivo. Chicken chorioallantoic membrane (CAM) assay shows tumor without myricetin treatment, and 
treated with 20 µM myricetin. After 5 days of treatment, the tumors were excised. Weight of xenografted tumor implanted on CAM treated with and without 
myricetin (0 and 20 µM). *p<0.05 as compared to control.
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Similarly, myricetin also reduced viability of OVCAR-3 
cells at concentrations of 10 µM myricetin and above. Cell 
viability was significantly decreased from 71.5% at a concen-
tration of 10 µM myricetin to 12.5% at a concentration of 
80 µM myricetin (p<0.05) (Fig. 1B). We also examined the 
growth-inhibitory activity of myricetin on IOSE-364 normal 
ovarian cells (Fig. 1B). Myricetin had higher level of cyto-
toxicity in ovarian cancer cells A2780/CP70 and OVCAR-3 
than on normal ovarian cells IOSE-364, indicating that 
cisplatin-resistant ovarian cancer cells were more sensitive 
to myricetin than normal ovarian cells. In CAM models, 
myricetin reduced typical tumor growth of OVCAR-3 cells. 
The tumors treated with 20 µM myricetin were smaller and 
lighter than corresponding controls (Fig. 1C).
Myricetin induces apoptosis in A2780/CP70 and OVCAR-3 
cells. For the purpose of investigating whether myricetin 
inhibited cell growth by inducing apoptosis, the apoptosis 
rates of ovarian cancer cell lines A2780/CP70, OVCAR-3, 
and normal ovarian cells IOSE-364 were treated with myric-
etin (5-30 µM) for 24 h, and analyzed by flow cytometry after 
Annexin V and propidium iodide (PI) staining. As shown in 
Fig. 2A, myricetin significantly induced apoptosis in the two 
ovarian cancer cells, especially in OVCAR-3, but it did not 
induce apoptosis in the normal ovarian cells IOSE-364. For 
A2780/CP70 and OVCAR-3, the apoptosis rates were 3.0 and 
3.8% when not treated with myricetin, which was increased 
to the maximum apoptosis rates of 42.1 and 84.2% at the 
concentration of 30 µM myricetin. However, the treatment of 
myricetin did not increase the IOSE-364 cell apoptosis rate 
(Fig. 2A). Caspase-Glo 3/7 Assay kit was used to confirm 
that myricetin induces apoptosis in ovarian cancer cells. 
As shown in Fig. 2B, compared to controls, the caspase-3/7 
enzymatic activities were maximally increased to 1.68- and 
2.20-fold in A2780/CP70 and OVCAR-3 when treated with 
20 µM myricetin for 4 h. These results indicate that myricetin 
inhibited cell growth of ovarian cancer cells at least partly 
through the induction of apoptosis.
Myricetin does not induce cell cycle arrest in A2780/CP70 
and OVCAR-3 cells. To investigate whether the growth-
inhibitory effect of myricetin on ovarian cancer cells was 
Figure 2. Myricetin induced apoptosis in ovarian cancer cells A2780/CP70 and OVCAR-3 but not the normal ovarian cells IOSE-364. (A) Cells treated with 
myricetin for 24 h, were collected, stained with PI and Annexin V, analyzed by flow cytometry to measure the apoptotic rate. (B) Cells were treated with 
myricetin for 4 h, and caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to control.
Figure 3. Myricetin did not induce cell cycle arrest in ovarian cancer cells A2780/CP70 and OVCAR-3. Cells treated with myricetin for 24 h, were collected, 
stained with PI, analyzed by flow cytometry to measure cell phase division.
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caused by cell cycle arrest, cell cycle phase distribution of 
cells treated with myricetin (5-20 µM) for 24 h was analyzed 
by flow cytometry after PI staining. As shown in Fig. 3, 
myricetin had little effect on inducing cell cycle arrest in 
A2780/CP70 and OVCAR-3 cells. These results indicate that 
myricetin inhibited ovarian cancer cell growth through a 
mechanism separate from cell cycle arrest.
Effect of myricetin on the intrinsic and extrinsic apoptotic 
pathway. The intrinsic apoptotic pathway and extrinsic 
apoptotic pathway are the two main pathways which induce 
apoptosis in cancer cells. An investigation was conducted to 
determine whether myricetin induces apoptosis through the 
intrinsic pathway in ovarian cancer cell lines A2780/CP70 
and OVCAR-3. The expression of Puma, Bcl-2, Bcl-xl, Bax, 
Bad and caspase-9 proteins were detected by western blot-
ting. As shown in Fig. 4A, the expression of Bax and Bad 
proteins was increased, while the Bcl-2 and Bcl-xl protein 
levels were decreased when treated with myricetin. However, 
the procaspase-9 and Puma protein levels were not changed 
by treatment with myricetin. The cleaved caspase-9 protein 
was not detected, suggesting that it may be degraded after 
activation from procaspase-9. Caspase-Glo 9 Assay kit 
was used to detect changes in caspase-9 enzymatic activi-
ties when treated with myricetin. The test was found to be 
consistent with the western blotting result, which shows that 
myricetin had no effect on the caspase-9 enzymatic activities 
of A2780/CP70 and OVCAR-3 cells (Fig. 4B). These results 
indicate that myricetin might induce the intrinsic pathway 
in A2780/CP70 and OVCAR-3 cells through Bcl-2 family 
proteins.
Next, the role of the extrinsic pathway in myricetin-
induced apoptosis was determined. Myricetin increased 
the expression of matured DR5 and decreased the levels of 
procaspase-8 in OVCAR-3 cells but not A2780/CP70 cells 
(Fig. 4C). FADD protein levels were not changed in both 
ovarian cancer cell lines treated with myricetin. Myricetin 
might induce the extrinsic pathway in OVCAR-3 cells 
through a DR5 and caspase-8 dependent pathway. However, 
the induction of apoptosis in A2780/CP70 cells might be 
through an extrinsic-independent pathway.
Role of p53 in the myricetin-induced apoptosis in OVCAR-3 
cells. P53, a tumor suppressor protein, is involved in several 
cellular outcomes such as apoptosis and angiogenesis (20). 
Therefore, we examined some proteins which are associ-
ated with p53 to clarify whether myricetin inhibits viability 
in A2780/CP70 and OVCAR-3 cells via the p53 protein 
(Fig. 5A). We found that myricetin upregulated expression 
of the p53 and p21 proteins and downregulated expression of 
the oncogene cmyc protein.
The inhibitor of pifithrin-α (PFT-α) was used to inves-
tigate the role of p53 on myricetin-induced apoptosis in 
OVCAR-3 cells. Treatment with 20 µM pifithrin-α signifi-
cantly reduced the apoptotic rates and caspase-3/7 enzymatic 
activities in OVCAR-3 cells induced by myricetin (Fig. 5B 
and C). Fig. 5D shows knockdown of p53 by specific siRNA 
(50 nM) resulted in abrogation of myricetin-increased levels 
of Bax, Bad, and p21 proteins and myricetin-decreased 
levels of cmyc and Bcl-xl proteins. These results indicate 
that p53-associated intrinsic pathways were, at least partly, 
involved in myricetin-induced apoptosis in ovarian cancer 
cells.
Role of p21 in the myricetin-induced apoptosis in OVCAR-3 
cells. The p21 siRNA was used to investigate the role of 
Figure 4. Myricetin activated the intrinsic and extrinsic apoptotic pathway. (A) Myricetin decreased the levels of procaspase-9, Bcl-2 and Bcl-xl and increased 
levels of Bad and Bax in A2780/CP70 and OVCAR-3 ovarian cancer cells. However, myricetin had no effect on the expression of Puma protein. (B) Cells 
were treated with myricetin 4 h, and determined caspase-9 enzymatic activities using Caspase-Glo 9 Assay kit. *p<0.05 as compared to control. (C) Myricetin 
decreased the levels of procaspase-8 and increased levels of DR5 (p40) in OVCAR-3 but not A2780/CP70 cells. However, myricetin had no effect on the 
expression of FADD in either of the ovarian cancer cells.
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p21 on myricetin-induced apoptosis in OVCAR-3 cells. 
knockdown of p21 by siRNA (50 nM) did not abrogate the 
apoptosis and caspase-3/7 enzymatic activation in OVCAR-3 
cells which was induced by treatment of myricetin (Fig. 6). 
These results indicate that myricetin induced apoptosis in 
OVCAR-3 cells through a p21-independent pathway.
Discussion
A pressing problem in cancer treatment is that platinum-
based chemotherapy is seriously hampered by high rates 
of adverse effects and chemoresistance (21). There exists a 
dire need for more selective drugs in the treatment of cancer. 
Figure 5. Myricetin induces apoptosis on ovarian cancer cells in a p53-dependent pathway. (A) Myricetin decreased the expression of protein cmyc, and 
increased levels of protein p21 and p53. (B) Cells were treated with myricetin and p53 inhibitor pifithrin-α (PFT-α) for 24 h, stained with Hoechst 33342, 
apoptotic rate measured by fluorescence microscope. *p<0.05 as compared to myricetin-treated control. (C) Cells were treated with myricetin and PFT-α for 
4 h, and caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to myricetin-treated control. (D) knockdown 
p53 resulted in abrogation of myricetin-increased levels of Bad, Bax, p21 and p53 and decreased levels of cmyc, Bcl-2 and Bcl-xl in OVCAR-3 cells. Cells were 
seeded in 60-mm dishes, incubated overnight, and then transfected with p53 siRNA or control siRNA. After 24 h, cells were treated with myricetin or DMSO. 
Cell lysates were collected for western blotting.
Figure 6. Myricetin induces apoptosis on ovarian cancer cells in a p21-independent pathway. (A) knockdown p21 had no effect on the myricetin-induced 
apoptosis in OVCAR -3 cells. Cells were seeded in 60-mm dishes, incubated overnight, and then transfected with p21 siRNA or control siRNA. After 24 h, 
cells were treated with myricetin or DMSO for another 24 h, stained with Hoechst 33342, apoptotic rate was measured by fluorescence microscope. *p<0.05 
as compared to myricetin-treated control. (B) Cells were transfected with p21 siRNA or control siRNA for 24 h, treated with myricetin or DMSO for another 
24 h, caspase-3/7 enzymatic activity was determined using Caspase-Glo 3/7 assay kit. *p<0.05 as compared to myricetin-treated control.
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Previous studies have reported that myricetin induces apop-
tosis in various cancer cells, such as hepatoma, pancreatic 
cancer, esophageal cancer, and colon carcinoma cells 
(15-18). However, its effects on ovarian cancer are currently 
unknown. In this study, it was found that myricetin was more 
cytotoxic to two cisplatin-resistant ovarian cancer cell lines 
A2780/CP70 and OVCAR-3 than normal ovarian cells IOSE-
364, and that myricetin had stronger anticancer activity than 
cisplatin in the two ovarian cancer cell lines when compared 
to our previous study (19).
The mechanism through which cancer cells develop 
resistance to chemotherapy is associated with increased 
resistance to apoptosis. In pre-clinical disease models, agents 
that induce apoptosis have been reported to sensitize tumor 
cells to chemotherapy and radiotherapy (22). There are two 
major pathways leading to apoptosis: the intrinsic or mito-
chondrial and extrinsic or receptor-mediated pathways. The 
permeability of the mitochondria and release of cytochrome c 
into the cytoplasm will be increased when the intrinsic apop-
totic pathway is activated. After that, cytochrome c forms a 
multi-protein complex, known as the apoptosome, initiating 
activation of caspase-9. Bcl-2 protein family plays an impor-
tant role in the regulation of the intrinsic apoptotic pathway 
through controlling the permeability of the mitochondrial 
membrane and the release of pro-apoptotic factors (10). 
Whether or not cells will undergo apoptosis is dependent on 
the balance between the pro- (such as Bax and Bad) and anti-
apoptotic (such as Bcl-xl and Bcl-2) proteins of the family 
members. In the extrinsic pathway, tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), including the 
Apo2L/TRAIL, regulates the extrinsic apoptotic pathway by 
engaging its receptor, such as DR5. The receptor homotypi-
cally binds to FAS-associated death domain protein (FADD) 
to form death inducing signaling complex (DISC), activating 
caspase-8 and -10. Activation of either the intrinsic pathway 
of apoptosis or the extrinsic pathway results in activation 
of caspase-3 and -7 culminating in apoptosis. In this study, 
myricetin was found to induce intrinsic apoptosis through 
the Bcl-2 protein but not the caspase-9 enzyme in A2780/
CP70 and OVCAR-3 cells. A previous study indicated that 
myricetin induces apoptosis in colon cancer cells through 
increasing the ratio of Bax/Bcl-2 proteins (18), which agrees 
with the results obtained here. The effect of myricetin on the 
extrinsic apoptotic pathway was also examined by testing the 
expression of DR5, FADD, and caspase-8 proteins. It was 
found that myricetin increased the levels of DR5 protein and 
decreased the levels of procaspase-8 in the OVCAR-3 but 
not the A2780/CP70 cells, suggesting that myricetin induces 
apoptosis in OVCAR-3 cells though a DR5-associated 
extrinsic pathway. The alterations in the balance of Bcl-2/
Bax proteins was associated with the differential induction of 
apoptosis in cancer versus normal cells (23). Evidence from 
clinical trials has indicated that normal cells are resistant to 
the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), and targeting DR5 selectively eliminates tumor 
cells while sparing normal cells (24). This study has shown 
that myricetin induced apoptosis in ovarian cancer cells 
A2780/CP70 and OVCAR-3 but not normal ovarian cells 
IOSE-364, which might be due to its effects on the expression 
of the Bcl-2 family and DR5 protein.
The cell cycle represents a series of events that allow 
the cell to replicate into two daughter cells. Many cancer 
cells have defective G1 checkpoint mechanisms and are 
more dependent on the G2 checkpoint during replication 
than normal cells. Cancer represents a dysregulation of the 
cell cycle, such as an overexpression of cyclins or insuffi-
cient expression of CDkIs, which result in cell growth and 
tumor formation (7). Therefore, the innovative strategy of 
cell cycle arrest, which activates the apoptotic cascade and 
leads to cell death, was developed. Novel anticancer drugs 
have been focused on as the target of cell cycle control 
mechanisms (8,9). Previous studies indicated that myricetin 
induces G2/M blockage in human squamous cell carcinoma 
cell lines SCC-25 and human colon cancer cell lines HCT116 
(25,26). However, in the present study, the cell cycle in 
human ovarian cancer cells was not affected by treatment of 
myricetin, which means myricetin inhibited ovarian cancer 
cell growth through a mechanism separate from inducing 
cell cycle arrest.
p53, as a multifunctional tumor suppressor, regulates 
cell cycle arrest, transcription, DNA repair, genomic insta-
bility, senescence, differentiation, angiogenesis, apoptosis, 
and glucose metabolism (20). If the p53 gene is damaged, 
tumor suppression will be under serious threat. As shown 
in previous studies, p53 alterations, such as loss of function 
dominant-negative activity and gain of oncogene function, 
has been connected with the failure of chemotherapy and 
radiotherapy in a number of cancers (27). More than 50% of 
human tumors contain p53 gene that is mutated or deleted 
(28), and people who have only one functional copy of the 
p53 gene will probably suffer from tumors in early adult-
hood. Therefore, increasing the amount of p53 might be a 
new strategy for treatment of tumors. The intrinsic pathways 
of apoptosis such as Bax, Puma, and Noxa are regulated by 
p53 (29). It has been reported that the Bcl-2 family genes 
are regulated by p53, and cancer cells with loss of p53 func-
tion are expected to contain relatively low levels of Bax, 
Bad and high levels of Bcl-2 and Bcl-xl (30,31). In ovarian 
cancer cells, p53 also has an effect on cell apoptosis (32). 
In the present study, myricetin was observed to increase p53 
protein expression in the ovarian cancer cells. In OVCAR-3 
cells, the myricetin-induced balance alterations of Bcl-2 
family proteins were associated with increased p53 protein, 
indicating that p53 played an important role in the myricetin-
activated intrinsic pathway of apoptosis. The transcription 
factor cmyc protein is encoded by a regulator. It is a nuclear 
protein which plays a role in the cell cycle, apoptosis, progres-
sion, and cellular transformation. Previous studies indicated 
that p53-dependent repression of cmyc was involved in cell 
cycle arrest and apoptosis (33,34). In this study, myricetin 
decreased the cmyc protein expression in A2780/CP70 and 
OVCAR-3 cells, and knockdown of protein p53 neutralized 
the repressive effect myricetin had on cmyc expression in 
OVCAR-3 cells. Therefore, it is reasonable to think that 
p53 induced apoptosis through a cmyc-dependent manner. 
Of course, more studies are needed to clarify the role of 
cmyc in myricetin-induced apoptosis in ovarian cancer cells. 
Additionally, it was seen that myricetin increased the expres-
sion of p21 protein in both ovarian cancer cell lines, and it 
was mediated by p53 in OVCAR-3 cells. Therefore, it was 
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inferred that p21 might be involved in myricetin-induced 
apoptosis and the inhibition of angiogenesis in OVCAR-3 
cells.
P21, known as CDk-interacting protein 1 or cyclin-
dependent kinase inhibitor 1, regulates cell cycle progression, 
tightly regulated by p53 protein (35). It has been reported 
that myricetin increased levels of p21 protein in HepG2 cells 
which resulted in cell cycle arrest at the G2/M phase (36). 
However, in the present study, the increased levels of p21 
protein had little effect on the cell cycle in A2780/CP70 and 
OVCAR-3 cells. Some previous studies indicated that p21 was 
a positive regulator of apoptosis in either p53-dependent or 
independent pathways, while other studies showed p21 inhib-
ited p53-dependent apoptosis (37). In our study, although 
myricetin increased levels of p21 protein in OVCAR-3 cells, 
it was not associated with apoptosis.
In conclusion, the present study suggests that myricetin, 
which exhibited higher cytotoxicity to two cisplatin-resistant 
ovarian cancer cell lines than in normal ovarian cells, 
might be a potential candidate for the chemoprevention of 
ovarian cancer. It induces apoptosis in both ovarian cancer 
cells through a Bcl-2 family protein-associated intrinsic 
pathway. In OVCAR-3, myricetin also induces DR-5 associ-
ated extrinsic apoptosis. P53 plays an important role in Bcl-2 
family protein-dependent apoptosis, induced by myricetin, in 
OVCAR-3 cells. Ostensibly, further studies in animal models 
and human trials are needed to determine the efficacy of this 
compound for the treatment of ovarian cancer.
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